Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
© The Author(s) 2024. Published by Oxford University Press..
BACKGROUND: A history of pre-administration of immune checkpoint inhibitors has been reported to be associated with good outcomes of ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell lung cancer (NSCLC). However, existing knowledge on the clinical significance of RAM and DOC following combined chemoimmunotherapy is limited. Therefore, we evaluated the efficacy and safety of RAM plus DOC therapy after combined chemoimmunotherapy and attempted to identify the predictors of its outcomes.
PATIENTS AND METHODS: This multicenter, prospective study investigated the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events. An exploratory analysis measured serum cytokine levels at the start of treatment.
RESULTS: Overall, 44 patients were enrolled from 10 Japanese institutions between April 2020 and June 2022. The median PFS and OS were 6.3 and 22.6 months, respectively. Furthermore, the ORR and DCR were 36.4% and 72.7%, respectively. The high vascular endothelial growth factor D (VEGF-D) group had a significantly shorter PFS and OS. A combination of high VEGF-A and low VEGF-D levels was associated with a longer PFS.
CONCLUSION: Our results showed that RAM plus DOC after combined chemoimmunotherapy might be an effective and relatively feasible second-line treatment for patients with advanced NSCLC in a real-world setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The oncologist - (2024) vom: 18. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Katayama, Yuki [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Combined drug therapy |
|---|
| Anmerkungen: |
Date Revised 19.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/oncolo/oyae001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367316722 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367316722 | ||
| 003 | DE-627 | ||
| 005 | 20240120231903.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/oncolo/oyae001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1265.xml |
| 035 | |a (DE-627)NLM367316722 | ||
| 035 | |a (NLM)38241181 | ||
| 035 | |a (PII)oyae001 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Katayama, Yuki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 19.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press. | ||
| 520 | |a BACKGROUND: A history of pre-administration of immune checkpoint inhibitors has been reported to be associated with good outcomes of ramucirumab (RAM) plus docetaxel (DOC) combination therapy for advanced non-small-cell lung cancer (NSCLC). However, existing knowledge on the clinical significance of RAM and DOC following combined chemoimmunotherapy is limited. Therefore, we evaluated the efficacy and safety of RAM plus DOC therapy after combined chemoimmunotherapy and attempted to identify the predictors of its outcomes | ||
| 520 | |a PATIENTS AND METHODS: This multicenter, prospective study investigated the efficacy and safety of RAM plus DOC after combined chemoimmunotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence of adverse events. An exploratory analysis measured serum cytokine levels at the start of treatment | ||
| 520 | |a RESULTS: Overall, 44 patients were enrolled from 10 Japanese institutions between April 2020 and June 2022. The median PFS and OS were 6.3 and 22.6 months, respectively. Furthermore, the ORR and DCR were 36.4% and 72.7%, respectively. The high vascular endothelial growth factor D (VEGF-D) group had a significantly shorter PFS and OS. A combination of high VEGF-A and low VEGF-D levels was associated with a longer PFS | ||
| 520 | |a CONCLUSION: Our results showed that RAM plus DOC after combined chemoimmunotherapy might be an effective and relatively feasible second-line treatment for patients with advanced NSCLC in a real-world setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a VEGF-A | |
| 650 | 4 | |a VEGF-D | |
| 650 | 4 | |a combined drug therapy | |
| 650 | 4 | |a docetaxel | |
| 650 | 4 | |a non-small-cell lung carcinoma | |
| 650 | 4 | |a ramucirumab | |
| 700 | 1 | |a Yamada, Tadaaki |e verfasserin |4 aut | |
| 700 | 1 | |a Sawada, Ryo |e verfasserin |4 aut | |
| 700 | 1 | |a Kawachi, Hayato |e verfasserin |4 aut | |
| 700 | 1 | |a Morimoto, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Kageaki |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Chihara, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Shiotsu, Shinsuke |e verfasserin |4 aut | |
| 700 | 1 | |a Hibino, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Harada, Taishi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishioka, Naoya |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasaku, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tokuda, Shinsaku |e verfasserin |4 aut | |
| 700 | 1 | |a Takayama, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The oncologist |d 1998 |g (2024) vom: 18. Jan. |w (DE-627)NLM095483306 |x 1549-490X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:18 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/oncolo/oyae001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 18 |c 01 | ||